Agenda: To review and evaluate grant applications.

Place: The Westin Crystal City, 1800 Jefferson Davis Highway, Arlington, VA 22202.

Contact Person: Keith A. Mintzer, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7186, Bethesda, MD 20892–7924, 301–594–7947, mintzerk@nhlbi.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS).


Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016–12755 Filed 5–31–16; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs,” as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

<table>
<thead>
<tr>
<th>HHS-Certified Instrumented Initial Testing Facilities</th>
<th>Laboratory Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dynacare*</td>
<td>245 Pall Mall Street, London, ONT, Canada N6A 1P4</td>
</tr>
<tr>
<td></td>
<td>519–679–1630</td>
</tr>
<tr>
<td></td>
<td>(Formerly: Gamma-Dynacare Medical Laboratories)</td>
</tr>
<tr>
<td></td>
<td>8433 Quivira Road Lenexa, KS 66215–2802</td>
</tr>
<tr>
<td></td>
<td>800–445–6917</td>
</tr>
<tr>
<td></td>
<td>DrugScan, Inc. 200 Precision Road, Suite 200 Horsham, PA 19044</td>
</tr>
<tr>
<td></td>
<td>800–235–4890</td>
</tr>
<tr>
<td></td>
<td>Dynacare* Aegis Analytical Laboratories, Inc., Laboratory Specialists, Inc.)</td>
</tr>
</tbody>
</table>

If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at http://www.samhsa.gov/workplace.

FOR FURTHER INFORMATION CONTACT: Gillis Hersh, Division of Workplace Programs, SAMSHA/CSAP, 5600 Fishers Lane, Room 16N03A, Rockville, Maryland 20857; 240–276–2600 (voice).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs,” as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

<table>
<thead>
<tr>
<th>HHS-Certified Laboratories</th>
<th>Laboratory Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aegis Analytical Laboratories, Inc.</td>
<td>345 Hill Ave. Nashville, TN 37210</td>
</tr>
<tr>
<td>519–679–1630</td>
<td></td>
</tr>
<tr>
<td>(Formerly: Gamma-Dynacare Medical Laboratories)</td>
<td></td>
</tr>
<tr>
<td>8433 Quivira Road Lenexa, KS 66215–2802</td>
<td></td>
</tr>
<tr>
<td>800–445–6917</td>
<td></td>
</tr>
<tr>
<td>DrugScan, Inc. 200 Precision Road, Suite 200 Horsham, PA 19044</td>
<td></td>
</tr>
<tr>
<td>800–235–4890</td>
<td></td>
</tr>
<tr>
<td>Dynacare* Aegis Analytical Laboratories, Inc., Laboratory Specialists, Inc.)</td>
<td></td>
</tr>
</tbody>
</table>

If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at http://www.samhsa.gov/workplace.

FOR FURTHER INFORMATION CONTACT: Gillis Hersh, Division of Workplace Programs, SAMSHA/CSAP, 5600 Fishers Lane, Room 16N03A, Rockville, Maryland 20857; 240–276–2600 (voice).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs,” as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

<table>
<thead>
<tr>
<th>HHS-Certified Instrumented Initial Testing Facilities</th>
<th>Laboratory Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dynacare*</td>
<td>245 Pall Mall Street, London, ONT, Canada N6A 1P4</td>
</tr>
<tr>
<td></td>
<td>519–679–1630</td>
</tr>
<tr>
<td></td>
<td>(Formerly: Gamma-Dynacare Medical Laboratories)</td>
</tr>
<tr>
<td></td>
<td>8433 Quivira Road Lenexa, KS 66215–2802</td>
</tr>
<tr>
<td></td>
<td>800–445–6917</td>
</tr>
<tr>
<td></td>
<td>DrugScan, Inc. 200 Precision Road, Suite 200 Horsham, PA 19044</td>
</tr>
<tr>
<td></td>
<td>800–235–4890</td>
</tr>
<tr>
<td></td>
<td>Dynacare* Aegis Analytical Laboratories, Inc., Laboratory Specialists, Inc.)</td>
</tr>
</tbody>
</table>

If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at http://www.samhsa.gov/workplace.
Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group)

Laboratory Corporation of America

1120 Main Street
Southaven, MS 38671
866−827−8042/800−233−6339
(Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center)

LabOne, Inc. d/b/a Quest Diagnostics

10101 Renner Blvd.
Lenexa, KS 66219
913−888−3927/800−873−8845
(Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.)

MedTox Laboratories, Inc.

402 W. County Road D
St. Paul, MN 55112
651−636−7466/800−832−3244

MetroLab-Legacy Laboratory Services

1225 NE 2nd Ave.
Portland, OR 97232
503−413−3295/800−950−5295

Minneapolis Veterans Affairs Medical Center

Forensic Toxicology Laboratory

1 Veterans Drive
Minneapolis, MN 55417
612−725−2088
Testing for Veterans Affairs (VA) Employees Only

National Toxicology Laboratories, Inc.

1100 California Ave.
Bakersfield, CA 93304
661−322−4250/800−350−3515

One Source Toxicology Laboratory, Inc.

1213 Genoa-Red Bluff
Pasadena, TX 77504
888−747−3774
(Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory)

Pacific Toxicology Laboratories

9348 DeSoto Ave.
Chatsworth, CA 91311
800−326−6942
(Formerly: Centinela Hospital Airport Toxicology Laboratory)

Pathology Associates Medical Laboratories

110 West Cliff Dr.
Spokane, WA 99204
509−755−8991/800−541−7891 x7

Phamatech, Inc.

15175 Innovation Drive
San Diego, CA 92128
888−635−5840
Quest Diagnostics Incorporated

1777 Montreal Circle
Tucker, GA 30084
800−729−6432
(Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated

400 Egypt Road
Norristown, PA 19403
610−631−4600/877−642−2216
(Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated

8401 Fallbrook Ave.
West Hills, CA 91304
818−737−6370
(Formerly: SmithKline Beecham Clinical Laboratories)

Redwood Toxicology Laboratory

3700650 Westwind Blvd.
Santa Rosa, CA 95403
800−255−2159

Southwest Laboratories

4625 E. Cotton Center Boulevard
Suite 177
Phoenix, AZ 85040
602−438−8507/800−279−0027

STERLING Reference Laboratories

2617 East L Street
Tacoma, WA 98421
800−442−0438

US Army Forensic Toxicology Drug Testing Laboratory

2490 Wilson St.
Fort George G. Meade, MD 20755–5235
301−677−7085
Testing for Department of Defense (DoD) Employees Only

* The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 30, 2010 (75 FR 22809). After receiving DOT certification, the laboratory will be included in the monthly list of HHS-certified laboratories and participate in the NLCP certification maintenance program.

Summer King
Statistician.

[FR Doc. 2016–12809 Filed 5–31–16; 8:45 am]
BILLING CODE 4160–20–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

National Park Service


Niobrara Confluence and Ponca Bluffs Conservation Areas, NE and SD; Withdrawal of Draft Environmental Impact Statement and Land Protection Plan


ACTION: Notice of withdrawal.

SUMMARY: This notice advises the public that we, the U.S. Fish and Wildlife Service (FWS) and the National Park Service (NPS), as lead agencies, are withdrawing our proposal to establish the Niobrara Confluence and Ponca Bluffs Conservation Areas in Nebraska and South Dakota.

DATES: This action will become effective with this notice.

FOR FURTHER INFORMATION CONTACT: Toni Griffin, Acting Chief of Refuge Planning, U.S. Fish and Wildlife Service, P.O. Box 25486, DFC, Denver, CO 80225. Telephone (303) 236–4378.

SUPPLEMENTARY INFORMATION: On February 15, 2012, the FWS and the NPS, as lead agencies, published a notice of intent (77 FR 8992) to prepare an environmental impact statement (EIS) for the proposed Niobrara Confluence Conservation Area and Ponca Bluffs Conservation Area in Nebraska and South Dakota. On April 8, 2013, a draft EIS and land protection plan (LPP) were made available for public review and comment (78 FR 20942). In these documents, we described alternatives, including our proposed action, for implementing conservation actions along the Missouri River and its tributaries.

However, after considering the public comments received and analyzing other priorities for each agency, the FWS and NPS are hereby withdrawing the DEIS for the Niobrara Confluence and Ponca Bluffs Conservation Areas.